
Research

Leppä, AM., Grimes, K., Jeong, H. et al. Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype. Nat Genet 56, 2790–2803 (2024). https://doi.org/10.1038/s41588-024-01999-x Abstract Chromosomal instability is a major driver of intratumoral heterogeneity (ITH), promoting tumor progression. In the present study, we combined structural variant discovery and nucleosome occupancy profiling with […]
read more
BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial
Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation / exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing efficacy and safety of bemdaneprocel in people living with moderate Parkinson’s disease / Expected to be initiated in H1 2025, exPDite-2 is […]
read more
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new […]
read more
Sweet gene regulation in the mammalian embryo
EMBL researchers showed for the first time that adding a sugar to proteins inside cells is crucial for embryo development and for shutting down completely harmful parts of the genome in vivo Protein modifications are key to cell survival because they ensure they do what they are supposed to do in a healthy system. One […]
read more
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Previously, in Cohort 6, dose […]
read more
With lipid nanoparticles (LNPs), PROGEN offers an alternative drug delivery tool for the gene therapy market
Non-viral platform for efficient drug transfer to facilitate clinical developments Heidelberg, 15.01.2025 – PROGEN, leading manufacturer of Adeno-Associated-Virus (AAV) analytical tools for gene therapy research and development, announces the launch of LNPs for the versatile delivery of therapeutic agents into cells. In the past decade, PROGEN has driven progress in gene therapy by providing reliable […]
read more
New strategic partnership for AI in the sciences
EMBL and ELLIS deepen relationship to drive artificial intelligence (AI) in European life science research, training, and technology A new collaborative agreement aims to help position Europe at the forefront of AI-driven advancements in life sciences research. The European Molecular Biology Laboratory (EMBL) and the European Laboratory for Learning and Intelligent Systems (ELLIS) have agreed […]
read more
Researchers uncover what drives aggressive bone cancer
Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes Summary Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a significant impact on young people […]
read more
Epigenetics ensures placenta functioning
If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene […]
read more